Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brady Cobb
- Sector
- Consumer Defensive
- Industry
- Beverages - Wineries & Distilleries
- Employees
- 2
- Beta
- -1.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -303.29
Financials
Revenue
$0.00-100.0%Net Income
$-2.05MEBITDA
$-2.01M-41125.3%Free Cash Flow
$-1.08M-424806.3%EPS (diluted)
$-0.67Shares Outstanding (diluted)
3.06M+12945.5%Operating Expenses
$854.3KCash & Debt
$242.7KReturn of Capital
$0.00Revenue by Segment (annual)
$73.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $73.1K | $-25.23M | $-47.88 |
| 2024 | $4.16M | $-23.76M | $-70.72 |
| 2023 | $18.85M | $-21.00M | $-79.17 |
| 2022 | $18.09M | $-21.84M | $-92.60 |
| 2021 | $11.32M | $-29.05M | $-160.83 |
| 2020 | $2.30M | $-28.67M | $-19.84 |
| 2019 | $1.02M | $-5.14M | $-0.48 |
| 2018 | $1.31M | $68.2K | $0.07 |
| 2017 | $895.3K | $-147.5K | $-0.16 |
| 2016 | $1.01M | $-48.8K | $-0.05 |
| 2015 | $897.3K | $19.2K | $0.02 |
| 2014 | $605.9K | $-30.1K | $-0.03 |
| 2013 | $475.3K | $-3.2K | $-0.00 |
| 2012 | $308.7K | $-12.6K | $-0.01 |
Valuation
SBEVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·42d ago·Negative
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program FORT LAUDERDALE, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) ("Endovia Health" or the "Company") announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday FORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker symbol “EDVA” effective at market open at 9:30 a.m.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences FORT LAUDERDALE, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided an update on the Company's ongoing strategic transformation toward Endovia Health Sciences.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Splash Beverage Group to Rebrand as Endovia Health Sciences FORT LAUDERDALE, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the "Company") today announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026.
View source ↗
Earnings
Wed, Nov 18(in 6 weeks)
Consensus estimate $-12.80 per share
Typical surprise +54.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.77 vs $-12.80beat
- Wed, May 20$-1.88 vs $-12.80beat
- Wed, Feb 25$-5.88 vs $-12.80beat
- Wed, Nov 19$-18.04 vs $-11.20miss
- Wed, Aug 6$-7.88 vs $-12.80beat
- Wed, May 21$-7.88 vs $-12.80beat
Estimates and results for SBEV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SBEV officers and directors.
- Bought
- $74k
- Sold
- $272k
18 trades
1 trade
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
- Nistico Robertbought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SBEV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.